ECKERT & ZIEGLER RADIOPHARMA, INC.

Eckert & Ziegler Radiopharma, Inc. specializes in the production and distribution of radiopharmaceuticals for diagnostic and therapeutic applications in nuclear medicine. The company leverages advanced radiochemistry and GMP-compliant manufacturing processes to develop targeted radiotracer products used in PET and SPECT imaging, as well as alpha- and beta-emitter therapies. Their technical expertise includes isotope separation, radiolabeling of biomolecules, cold kit formulation, and aseptic processing under strict regulatory controls. Key differentiators include proprietary synthesis platforms, automated radiopharmaceutical production systems, and validated logistics networks supporting just-in-time delivery to hospitals and nuclear medicine centers. Award history does not provide sufficient detail to identify specific federal agencies or contract vehicles supported. Therefore, no definitive agency relationships or programmatic work patterns can be inferred from available data. The company operates within the radiopharmaceutical manufacturing sector, which aligns with NAICS categories related to pharmaceutical and medicine manufacturing, though no specific NAICS codes are available from their contract history. Their market positioning centers on supplying critical radiopharmaceuticals to clinical and research institutions requiring isotopes with short half-lives and high specific activity, often serving as a specialized link in the medical imaging supply chain. Eckert & Ziegler Radiopharma, Inc. is structured as a 2-level entity headquartered in Wilmington, Massachusetts. The company holds no government-recognized certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is focused on the Northeastern U.S., with operations tailored to meet the demands of regional healthcare networks and research facilities requiring reliable access to short-lived radioisotopes. The firm’s government market presence, while not documented through public contract awards, is likely aligned with defense, VA, or NIH-supported nuclear medicine initiatives through indirect supply channels.